Clinical trials: Second-line Therapy
HIV
Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens
Highly active antiretroviral therapy (HAART) transformed a once fatal condition into a chronic, manageable condition. However, it is estimated that 20-40% of patients on 2nd line treatment (2 nucleotide reverse transcriptase…
- Trial name
- ATF (NCT02689895)
- Testing
- modified directly administered anti-retroviral therapy (mDAART)
- Where
- 2 sites in Zimbabwe
- Volunteers
- 50 people
- Sponsor
- University of Zimbabwe
Mediterranean Fever, Colchicine Resistance
Study of Colchicine Resistance in Familial Mediterranean Fever
Five to 10% of familial mediterranean patients are considered colchicine-resistant (i.e. patients with a persistent inflammatory syndrome, despite taking the maximum tolerated dose of colchicine daily).
- Trial name
- COLCHI-RESIST (NCT05418686)
- Testing
- Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Gastric Adenocarcinoma
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
Phase Ib/II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced gastric adenocarcinoma patients with MET amplification as a second-line treatment.
- Trial name
- NCT02447406
- Testing
- AZD6094, docetaxel
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Samsung Medical Center
HIV, Tuberculosis
EARNEST Rifabutin Pharmacokinetics (PK) Substudy
Background and study aims? Some of the drugs used to treat HIV (anti-retrovirals, or ARVs) can affect the blood levels of other drugs used to treat TB - called a "drug-drug interaction".
- Trial name
- NCT01663168
- Testing
- Rifabutin
- Where
- 9 sites in Uganda
- Volunteers
- 140 people
- Sponsor
- Justine Boles
Esophageal Cancer
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
There is a need for more effective therapy for patients with esophageal squamous cell carcinoma who developed disease progression after first line therapy. Currently, there is no standard second-line therapy for this disease.
- Trial name
- NCT01806649
- Testing
- BKM120
- Where
- Thailand
- Volunteers
- 5 people
- Sponsor
- Prince of Songkla University
HIV Infections
A PK and Salvage Study for Children With HIV-infection
To evaluate the pharmacokinetics (PK) of LPV/r with saquinavir in HIV-1 infected children. To evaluate treatment response (clinical, immunological and virological) to LPV/r, SQV in Thai children.
- Trial name
- NCT00476359
- Testing
- Lopinavir/r plus saquinavir
- Where
- 3 sites in Thailand
- Volunteers
- 50 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Advanced Gastric Cancer
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
Because well-designed, randomized, controlled clinical trials are lacking in patients with advanced gastric cancer (AGC), and because randomly allocating patients to treatments that do not accord with their preferences may…
- Trial name
- NCT00821990
- Testing
- Chemotherapy, Best supportive care
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Advanced Gastric Adenocarcinoma
Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
Phase II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced gastric adenocarcinoma patients with MET overexpression as a second-line treatment.
- Trial name
- NCT02447380
- Testing
- AZD6094, Docetaxel
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Samsung Medical Center
HER2-positive Advanced Gastric Cancer
Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy
This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line…
- Trial name
- TREAZURE (NCT05640830)
- Testing
- trastuzumab, bevacizumab with paclitaxel (triple combination)
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Kangbuk Samsung Hospital
HIV Infection
ODYSSEY (PENTA 20)
A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.
- Trial name
- NCT02259127
- Testing
- Dolutegravir, Standard of Care
- Where
- 28 sites in Germany, Portugal and 6 more
- Volunteers
- 792 people
- Sponsor
- PENTA Foundation
Diabetic Neuropathies
Botulinum Toxin Type A in Diabetic Peripheral Neuropathy
Background: Diabetes mellitus is commonly complicated by diabetic peripheral neuropathy. Due to common side effects and poor tolerance to medication, poor adherence to medication is common in diabetic peripheral neuropathy.
- Trial name
- NCT05296759
- Testing
- botulinum toxin A, Gabapentin, Duloxetine
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Colorectal Cancer
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China.
- Trial name
- NCT04431791
- Testing
- Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Peking University
Hepatocellular Carcinoma (HCC), Second Line Treatment
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
The goal of this prospective Phase II clinical trial is to evaluate the efficacy and safety of QL1706-based combination therapy in patients with hepatocellular carcinoma (HCC) who have failed prior targeted-immunotherapy (e.g.…
- Trial name
- DRIVE-II (NCT07138885)
- Testing
- HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Nocturia
Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men
The aim of the present study was to determine whether the combined administration of a diuretic agent, hydrochlorothiazide, at night would improve the frequency of nocturia unresponsive to alpha-blocker monotherapy in men with…
- Trial name
- NCT00700583
- Testing
- combination therapy of terazosin and hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Seoul National University Hospital
Pulmonary Tuberculosis
Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament
In all treatments of tuberculosis, the second-line drugs are usually less effective but have more drug toxicity than the first-line ones.
- Trial name
- CSPK (NCT01002170)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taipei Medical University WanFang Hospital
Drug Resistant Epilepsy
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
The goal of this interventional study is to learn about the efficacy and safety of first line anti epileptic drugs (AEDs) as substitution therapy for children who are resistant to second-line AEDs.
- Trial name
- NCT05697614
- Testing
- Valproic acid, Carbamazepin, Phenytoin
- Where
- 3 sites in Indonesia
- Volunteers
- 100 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital